RU2018130106A - Вакцина против синтетических опиоидов - Google Patents

Вакцина против синтетических опиоидов Download PDF

Info

Publication number
RU2018130106A
RU2018130106A RU2018130106A RU2018130106A RU2018130106A RU 2018130106 A RU2018130106 A RU 2018130106A RU 2018130106 A RU2018130106 A RU 2018130106A RU 2018130106 A RU2018130106 A RU 2018130106A RU 2018130106 A RU2018130106 A RU 2018130106A
Authority
RU
Russia
Prior art keywords
vaccine
group
drug
fentanyl
patient
Prior art date
Application number
RU2018130106A
Other languages
English (en)
Russian (ru)
Other versions
RU2018130106A3 (cg-RX-API-DMAC7.html
Inventor
Ким Д. ДЖАНДА
Original Assignee
Дзе Скриппс Рисерч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Скриппс Рисерч Инститьют filed Critical Дзе Скриппс Рисерч Инститьют
Publication of RU2018130106A publication Critical patent/RU2018130106A/ru
Publication of RU2018130106A3 publication Critical patent/RU2018130106A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018130106A 2016-01-21 2017-01-18 Вакцина против синтетических опиоидов RU2018130106A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281262P 2016-01-21 2016-01-21
US62/281,262 2016-01-21
PCT/US2017/013865 WO2017127390A1 (en) 2016-01-21 2017-01-18 Synthetic opioid vaccine

Publications (2)

Publication Number Publication Date
RU2018130106A true RU2018130106A (ru) 2020-02-21
RU2018130106A3 RU2018130106A3 (cg-RX-API-DMAC7.html) 2020-05-26

Family

ID=59362842

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018130106A RU2018130106A (ru) 2016-01-21 2017-01-18 Вакцина против синтетических опиоидов

Country Status (7)

Country Link
US (1) US11305010B2 (cg-RX-API-DMAC7.html)
EP (1) EP3405475B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019506390A (cg-RX-API-DMAC7.html)
CN (1) CN108884127A (cg-RX-API-DMAC7.html)
BR (1) BR112018014908A2 (cg-RX-API-DMAC7.html)
RU (1) RU2018130106A (cg-RX-API-DMAC7.html)
WO (1) WO2017127390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660331B2 (en) 2017-11-09 2023-05-30 The Scripps Research Institute Heroin vaccine
WO2020006563A1 (en) * 2018-06-29 2020-01-02 Marquette University Fluorinated compounds as ph-sensitive analgesics
WO2021092446A1 (en) * 2019-11-08 2021-05-14 Regents Of The University Of Minnesota Fentanyl hapten, fentanyl hapten-conjugates, and methods for making and using
US20230100186A1 (en) * 2020-01-13 2023-03-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Fentanyl haptens for the preparation of a fentanyl vaccine
CA3175295A1 (en) * 2020-03-13 2021-09-16 Regents Of The University Of Minnesota Fentanyl haptens, fentanyl hapten conjugates, and methods for making and using
JP7839789B2 (ja) * 2020-11-10 2026-04-02 ザ スクリプス リサーチ インスティテュート オピオイド治療用抗体
US20240307517A1 (en) * 2021-05-10 2024-09-19 Cornell University Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addiction
WO2024215826A2 (en) * 2023-04-13 2024-10-17 Avicenna Biotech Research, Llc Compositions and methods for treating fentanyl dependence

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
EP0635019B1 (en) 1992-04-06 1999-05-26 Biosite Diagnostics Inc. Opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
US6262265B1 (en) 1999-06-18 2001-07-17 Microgenics Corporation Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
ATE358275T1 (de) * 2001-11-16 2007-04-15 Randox Lab Ltd Verfahren und kit zum nachweis, oder zum quantifizieren von, metaboliten von fentanyl und metaboliten von fentanyl analoga
NZ537003A (en) * 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
WO2004111202A2 (en) * 2003-03-07 2004-12-23 Incyte Corporation Neurotransmission-association proteins
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
CA2597098C (en) * 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
US20110182918A1 (en) * 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
US9296802B2 (en) * 2009-04-15 2016-03-29 Postech Academy-Industry Foundation Target-specific non-antibody protein and method for preparing the same
MX361929B (es) * 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
AU2012327223A1 (en) * 2011-11-30 2013-06-20 Wellstat Diagnostics, Llc. Assays, antibodies, immunogens and compositions related to 5-FU
CA2895702C (en) 2011-12-21 2020-03-31 The Scripps Research Institute Heroin haptens, immunoconjugates and related uses
US20140093525A1 (en) * 2012-09-17 2014-04-03 Minneapolis Medical Research Foundation Compositions and methods of treating opioid addiction
US9981043B2 (en) 2013-02-08 2018-05-29 Regents Of The University Of Minnesota Analgesic conjugates
US9213029B2 (en) * 2013-06-25 2015-12-15 Samsung Electronics Co., Ltd. Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients

Also Published As

Publication number Publication date
WO2017127390A1 (en) 2017-07-27
BR112018014908A2 (pt) 2018-12-18
CN108884127A (zh) 2018-11-23
US20210128720A1 (en) 2021-05-06
JP2019506390A (ja) 2019-03-07
CA3015336A1 (en) 2017-07-27
EP3405475B1 (en) 2022-09-28
EP3405475A4 (en) 2019-08-28
RU2018130106A3 (cg-RX-API-DMAC7.html) 2020-05-26
US11305010B2 (en) 2022-04-19
EP3405475A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
JP2019506390A5 (cg-RX-API-DMAC7.html)
KR940003057B1 (ko) 경구적(Oral) 전달방법
CY1118373T1 (el) Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος
RU2010107207A (ru) Новые синтетические агонисты tlr9
Crouse et al. A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models
CN103768595B (zh) 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗
Coban et al. The malarial metabolite hemozoin and its potential use as a vaccine adjuvant
US20070231344A1 (en) Conjugate vaccines for non-proteinaceous antigens
SE0301663D0 (sv) Analysmetod för infusionsläkemedel
Jacob et al. Investigations of enantiopure nicotine haptens using an adjuvanting carrier in anti-nicotine vaccine development
CN104623654A (zh) 壳寡糖的应用及含壳寡糖的疫苗剂
CU23917B1 (es) Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína
CN104096229B (zh) 甘氨酸锌佐剂及含甘氨酸锌佐剂的疫苗
CN101972477B (zh) 磷酸锌疫苗佐剂
US10487141B2 (en) Enantiopure haptens for nicotine vaccine development
CN104056266B (zh) 新喋呤佐剂及含新喋呤佐剂的疫苗
CN104667272A (zh) 一种动物免疫佐剂及其制备方法和使用方法
CN103736090B (zh) 甲磺酸去铁胺佐剂及含甲磺酸去铁胺佐剂的疫苗
JP2017515867A5 (cg-RX-API-DMAC7.html)
CN102085366A (zh) 一种复合疫苗佐剂
WO2007131017A3 (en) A METHOD FOR DELIVERING A HUMAN CHORIONIC GONADOTROPIN (hCG) VACCINE FOR LONG-ACTING ANTIBODY PRODUCTION
UA26447U (en) Method for producing immune sera
RU2012128562A (ru) Способ пролонгированного обезболивания в раннем послеоперационном периоде у больных геморроем iii-iv стадий
TH85786B (th) กรรมวิธีสำหรับการเตรียมและการใช้ไบลาเลนซ์วัตซีนต่อการการติดมอร์ฟีน-เอโรอีน
TW200711658A (en) Method for improving yield of immune antibodies in vaccine of animals and humans